KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 83 filers reported holding KEROS THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $2,261,524 | +113.5% | 34,162 | +28.2% | 0.00% | +100.0% |
| Q4 2023 | $1,059,286 | +34.0% | 26,642 | +7.4% | 0.00% | 0.0% |
| Q3 2023 | $790,593 | -27.1% | 24,799 | -8.1% | 0.00% | 0.0% |
| Q2 2023 | $1,084,137 | +31.8% | 26,982 | +40.0% | 0.00% | 0.0% |
| Q1 2023 | $822,873 | -1.5% | 19,271 | +10.8% | 0.00% | 0.0% |
| Q4 2022 | $835,212 | +123.3% | 17,393 | +74.9% | 0.00% | – |
| Q3 2022 | $374,000 | -4.8% | 9,947 | -30.0% | 0.00% | – |
| Q2 2022 | $393,000 | -16.9% | 14,215 | +63.1% | 0.00% | – |
| Q1 2022 | $473,000 | +3.3% | 8,715 | +11.5% | 0.00% | – |
| Q4 2021 | $458,000 | +38.0% | 7,819 | -6.7% | 0.00% | – |
| Q3 2021 | $332,000 | -6.7% | 8,379 | +0.1% | 0.00% | – |
| Q2 2021 | $356,000 | -7.8% | 8,367 | +33.2% | 0.00% | – |
| Q1 2021 | $386,000 | -64.0% | 6,281 | -58.7% | 0.00% | -100.0% |
| Q4 2020 | $1,073,000 | – | 15,213 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 276,000 | $7,626,000 | 3.44% |
| First Light Asset Management, LLC | 598,333 | $16,532,000 | 1.92% |
| Fairmount Funds Management LLC | 272,498 | $7,529,000 | 1.72% |
| Deep Track Capital, LP | 739,528 | $20,433,000 | 1.34% |
| Nantahala Capital Management | 911,901 | $25,196,000 | 1.26% |
| Octagon Capital Advisors LP | 152,249 | $4,207,000 | 1.12% |
| CHI Advisors LLC | 103,429 | $2,858,000 | 1.09% |
| Altium Capital Management LP | 88,000 | $2,431,000 | 0.97% |
| Orbimed Advisors | 1,679,417 | $46,402,000 | 0.84% |
| Parkman Healthcare Partners LLC | 47,788 | $1,320,000 | 0.49% |